Segment Evaluation and Major Growth Areas in the Multiomics Market

The multiomics market is poised for significant expansion as technological advancements and diverse applications continue to drive interest. With increasing integration of AI and a growing focus on personalized approaches, this field is set to play a crucial role in healthcare, agriculture, and research. Let's explore the expected market growth, key players, prevailing trends, and detailed segmentation shaping the multiomics landscape.

Projected Growth Trajectory of the Multiomics Market
The multiomics market is anticipated to experience rapid growth, reaching a valuation of $8.07 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 15.6%. Several factors contribute to this upward trend, including improvements in multiomics platforms, a rising demand for personalized medicine, and greater adoption of AI-powered analytics. Additionally, the expanding use of metabolomics in clinical environments and the application of multiomics in precision agriculture further bolster market growth. Key trends expected during the forecast period include increased adoption of single-cell multiomics, enhanced integration of multi-layer biological data, expanded use of multiomics for early disease diagnosis, growth in drug discovery pipelines, and broader application in agricultural genomics.

Download a free report of the multiomics market report:
https://www.thebusinessresearchcompany.com/report/multiomics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Prominent Companies Driving the Multiomics Market Forward
The multiomics sector features several leading organizations, including Bayer AG, Thermo Fisher Scientific Inc., Novartis AG, Becton dic*kinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Shimadzu Corporation, Bruker Corporation, Bio-Techne, Azenta Life Sciences, 10x Genomics, Ginkgo Bioworks, Abcam Limited, BioLegend, Oxford Nanopore Technologies Plc, Adaptive Biotechnologies, Pacific Biosciences, Standard BioTools, Parse Biosciences, Mission Bio, CD Genomics, Singleron Biotechnologies, Psomagen, and BGI Group.

Enhancing Capabilities Through Strategic Acquisitions in Multiomics
In July 2024, Anacura, a Belgium-based provider of medical and pharmaceutical analytical services, acquired OHMX.bio, a Ghent University spin-off known for its advanced "-omics" technologies. The acquisition, for an undisclosed amount, aims to strengthen Anacura's technological capabilities within multiomics, particularly to boost its drug discovery and diagnostics platforms. OHMX.bio specializes in combining next-generation sequencing, bioinformatics, and multi-omic analyses to accelerate the development of biologics and advanced therapies such as mRNA vaccines and CAR-T cells.

View the full multiomics market report:
https://www.thebusinessresearchcompany.com/report/multiomics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Technological Advances Shaping Future Trends in Multiomics
Companies in the multiomics field are increasingly focused on developing sophisticated biowearable sensors to improve monitoring and management of chronic kidney disease (CKD). These compact, non-invasive devices track vital kidney biomarkers like creatinine and urea in real time through sweat or interstitial fluid analysis. For instance, in April 2024, French biowearable technology company Metyos introduced a lightweight, wrist-worn biosensor that continuously measures key kidney health indicators. This device leverages advanced nanotechnology and AI-driven analytics to detect early kidney dysfunction, reducing the need for frequent blood tests and hospital visits. It also connects to a mobile app, providing personalized health insights and alerts for abnormal biomarker levels, facilitating timely intervention and proactive care.

Detailed Segment Breakdown of the Multiomics Market
This report segments the multiomics market into several categories:
1) By Type: Single-Cell Multiomics and Bulk Multiomics
2) By Platform: Genomics, Transcriptomics, Proteomics, Metabolomics, and Integrated Omics Platforms
3) By Application: Diagnostics, Drug Discovery and Development, Personalized Medicine, AgriGenomics, and Other Applications
4) By End User: Academics and Research Organizations, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, and Other End Users

Further breakdown of subsegments includes:
1) Single-Cell Multiomics covering Single-Cell Genomics, Transcriptomics, Epigenomics, Proteomics, and Metabolomics
2) Bulk Multiomics including Genomics, Transcriptomics, Epigenomics, Proteomics, and Metabolomics

This comprehensive segmentation provides a thorough understanding of the diverse areas within the multiomics market, highlighting the broad range of technologies and applications that are driving its growth.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.